Steatohepatitis

TAIPEI, Taiwan and SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis…

Alina M. Allen, M.D., Gastroenterology & Hepatology, Mayo Clinic: So the liver is a complex organ. It has a lot of functions. Patients with nonalcoholic fatty liver disease benefit from the Mayo care because we offer the best…

Wilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis therapeutics market stood at US$ 10.1 billion in 2021 and the global non-alcoholic steatohepatitis therapeutics market is…

<!-- Name:DistributionId Value:8844742 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates -- bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the…

NORCROSS, Ga., April 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its first data and safety monitoring board…

CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver…